HER2/neu peptide (GP2)-based breast cancer vaccines with GM-CSF as an adjuvant have shown promising results, with the GP2+GM-CSF vaccine combination capable of eliciting both ex vivo and in vivo immune responses [15,16,17,18]. This evidence concerns the gene GP2 and breast cancer.